Cartesian Therapeutics (RNAC) Research & Development (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Research & Development data on file, last reported at $19.5 million in Q1 2026.

• Research & Development for Q1 2026 came in at $19.5 million, up 32.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.8 million (up 25.54% YoY), and the FY2025 annual result was $58.0 million, up 28.66% from the prior year.
• Research & Development advanced to $19.5 million in Q1 2026 per RNAC's latest filing, from $14.7 million in the prior quarter.
• Over five years, Research & Development peaked at $21.9 million in Q4 2023 and troughed at $9.7 million in Q1 2024.
• A 5-year average of $15.7 million and a median of $14.9 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development slumped 48.26% in 2024, then surged 50.69% in 2025.
• A 5-year view of Research & Development shows it stood at $19.0 million in 2022, then increased by 15.21% to $21.9 million in 2023, then tumbled by 48.26% to $11.3 million in 2024, then grew by 29.92% to $14.7 million in 2025, then jumped by 32.5% to $19.5 million in 2026.
• Business Quant data shows RNAC's Research & Development at $19.5 million in Q1 2026, $14.7 million in Q4 2025, and $13.8 million in Q3 2025.